Turn this list into pipeline.
Biotech Companies in Cambridge: 100+ Active Firms (2026)
Biotech companies in Cambridge develop biological therapies, diagnostics and research platforms within a regulated UK life-sciences hub.
Buying centres tend to sit in R&D, translational medicine, clinical operations and biopharma partnering teams rather than conventional procurement. Cambridge-based suppliers often sell into pharmaceutical, healthcare, academic and clinical research customers, with engagements shaped by validation cycles, milestone funding and evidence generation. Therapeutic asset developers usually depend on outsourced clinical and manufacturing capacity, while diagnostics and enabling-platform businesses are more likely to combine service revenue with longer-term intellectual-property economics. The commercial motion is therefore slower and more specialist than in many software markets, with buyer diligence focused on reproducibility, regulatory pathway, sample access and the credibility of the scientific team.
Read more
Cambridge has 142 active biotechnology companies in this cohort, giving the city a compact but research-dense commercial base around biological therapeutics, diagnostics and enabling platforms. Reported employment totals 718 people, which points to a market made up largely of specialist teams rather than broad operating workforces. That shape is consistent with asset-development models that keep discovery, trial management or manufacturing partly external, and with university-adjacent companies that may remain small while they test biology, secure intellectual property and build clinical or pharmaceutical partnerships.
UK biotech and biopharmaceutical activity sits within the life-sciences regulatory framework overseen by the MHRA. Its role covers clinical trial applications, marketing authorisations and post-authorisation safety monitoring through pharmacovigilance. Clinical development also brings Good Clinical Practice, ethics review and informed-consent requirements into the operating model, so governance sits close to science from the outset. Market access adds a further layer: approved medicines may face NICE review before routine use in the health service. Sector representation is split across bodies such as the BioIndustry Association for biotech and the ABPI for research-based pharmaceutical companies.
Commercial progression appears likely to remain uneven. Cambridge has the research base and specialist labour pool to keep forming new biotech ventures, but the path from platform science to reimbursed product tends to be long, capital-intensive and exposed to trial risk. Many firms may continue to pair narrow internal teams with outsourced clinical, regulatory and manufacturing partners, which keeps headcount lean but raises dependence on external capacity. The small group that reaches material revenue scale is likely to shape acquisition interest and partnering activity, while earlier-stage companies remain sensitive to investor appetite and evidence thresholds.
142
Active firms
2026
5
Above £5M
reported revenue
34
Recent incorporations
formed since 2022
Key facts
About 3% of the trading cohort reports turnover above £5M (5 of 142 firms) — the rest sits below that revenue band.
23% of the cohort was incorporated since 2022 (34 firms), so a sizeable share is in its first few filing cycles.
Biotech and biopharmaceutical firms operate within MHRA clinical-trial approvals, marketing authorisations and post-authorisation pharmacovigilance.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements before therapies can move through UK approval pathways.
The Office for Life Sciences estimated the UK life-sciences industry at 6,170 businesses across 7,320 companies in 2023/2024, with £146.9 billion in turnover.
Biopharmaceuticals accounted for 2,960 companies and £98.9 billion in turnover in 2023/2024, equal to 67% of total life-sciences turnover.
BIA reported that UK biotech raised £3.5 billion in equity investment in 2024, up 94% on 2023 but still below £4.5 billion in 2021.
Top Cambridge biotech companies
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops biologic treatments for chronic wounds. Lead product Aurase Wound Gel is an investigational enzymatic therapy designed to debride wound tissue and stimulate repair pathways, and is…
Targets healthcare systems, wound care clinicians and patients with chronic, non-healing wounds, including those considering investigational or expanded-access treatment pathways.
Financial Health
WeakWeak · -2% CAGR over 4y
Location
Neobe Therapeutics
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops engineered live biotherapeutics for cancer treatment using synthetic biology. Designs programmable bacteria to modify the tumour microenvironment in solid tumours, aiming to enable or…
Targets oncology healthcare and biopharma stakeholders focused on patients with immune-excluded solid tumours; also engages academic synthetic biology and immunology partners and investors.
Financial Health
StrongStrong · Hiring · 27% CAGR over 3y
Location
Trajectory
2y · 2020–NowFinancial sub-scores
Computed from 2 filingsDevelops non-endoscopic diagnostic technologies for gastrointestinal diseases. Produces capsule sponge cell-collection devices and molecular tests, including EndoSign, used to detect and monitor…
Sells to healthcare providers and clinical researchers involved in gastrointestinal and oesophageal care, including community care settings focused on early detection and monitoring of Barrett’s…
Financial Health
StrongStrong · Hiring · 166% CAGR over 1y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides AI-powered imaging and data analysis services for clinical trials, including image management, biomarker development, and analysis of radiology and healthcare datasets to support drug…
Serves biopharma and pharmaceutical clinical trial sponsors developing lung and heart disease therapies, especially teams running trials in IPF, pulmonary fibrosis, pulmonary hypertension and…
Financial Health
StrongStrong · Hiring · 20% CAGR over 2y
Location
Trajectory
2y · 2021–NowFinancial sub-scores
Computed from 2 filingsDevelops targeted cancer immunotherapies, including a universal CAR T cell platform and antibody-based treatments targeting the nfP2X7 receptor. Conducts research and development of therapies for…
Targets the oncology healthcare market, with therapies intended for cancer patients suffering from a wide range of liquid and solid tumours worldwide.
Financial Health
StableStable · 0% CAGR over 1y
Location
Enedra Therapeutics
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops targeted cancer therapeutics using genomic data analysis and AI. Its CASPAROV platform analyses large cancer evolution datasets to identify shared vulnerabilities in heterogeneous tumours…
Targets cancer patients with genetically heterogeneous, treatment-resistant tumours, particularly those with limited or no effective options, and the oncology clinicians and healthcare systems…
Financial Health
StrongStrong · Hiring · 43% CAGR over 3y
Location
AVATRIAL LIMITED
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops platforms for cancer drug discovery using patient tissue samples, multi‑omics data generation, and machine learning analysis. Conducts experimental validation of therapeutic targets and…
Serves B2B partners in oncology drug discovery, including healthcare organisations, technology providers and research collaborators focused on personalised cancer treatment development.
Financial Health
WeakWeak
Location
Develops targeted cancer immunotherapies, including a universal CAR T platform (BRiDGECAR) that combines nfP2X7‑targeted CAR T cells with antibodies. Conducts research and development of treatments…
Targets oncology healthcare markets, ultimately serving cancer patients with liquid and solid tumours worldwide. The site also addresses life sciences investors and eligible existing shareholders.
Location
Trajectory
2y · 2023–NowDevelops laboratory technology for single‑cell functional analysis. Its Envisia platform uses droplet-based assays to study cell interactions, biomolecule secretion and targeted cell killing,…
Serves life sciences researchers and R&D teams in biotech, pharmaceutical, diagnostic and academic research organisations working in basic/translational research, drug discovery and therapeutic…
Financial Health
Insufficient historyInsufficient history
Location
Trimtech Therapeutics Limited
Trajectory
1y · 2025–NowDevelops protein-degrading therapeutics targeting disease-causing protein aggregates. Uses TRIM21-based technologies, including TRIMTAC and TRIMGLUE platforms, to design treatments for central…
Serves the healthcare market for CNS and inflammatory disorders, particularly patients with protein aggregation diseases and the clinicians or healthcare systems treating them.
Financial Health
Insufficient historyInsufficient history
Location
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops microfabricated microcarrier technology for biological assays, including barcoded SemaCyte micro‑wells that carry adherent cell colonies. Products enable multiplexed cell screening and…
Sells to B2B life sciences customers, particularly pharma, biotech, and research teams running automated adherent-cell assays, high-content screening, and in vitro drug discovery workflows.
Financial Health
StableStable · Hiring · 41% CAGR over 4y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops biotechnology for cellular rejuvenation. Uses machine learning, single‑cell sequencing and ageing‑clock models to identify gene targets and develop therapeutic candidates aimed at reversing…
Targets healthcare and life-sciences markets focused on age-driven diseases, with initial therapeutic indications including age-related hearing loss, liver fibrosis and systemic sclerosis.
Financial Health
StrongStrong · Hiring · 43% CAGR over 5y
Location
TIDALSENSE LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops respiratory diagnostic and monitoring technology using AI and breath analysis. Its N‑Tidal platform combines sensors, connected devices and cloud software to detect and monitor conditions…
Serves healthcare providers and payers, NHS respiratory care pathways, clinicians working with COPD and asthma patients, pharmaceutical companies, and patients with respiratory conditions.
Financial Health
StableStable · Hiring · 20% CAGR over 2y
Location
Exhalation Technology
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops breath‑analysis diagnostic technology for early detection of lung cancer. Its Inflammacheck device analyses biomarkers and breathing patterns in exhaled breath using sensors and AI to…
Sells to healthcare providers and health systems involved in lung cancer screening, including GP and outreach settings. Serves point-of-care and public health buyers seeking accessible screening for…
Financial Health
HealthyHealthy · Hiring · 10% CAGR over 2y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops AI software that analyses H&E‑stained tissue images to infer molecular and multi‑omics biomarker profiles. The technology provides rapid tissue analysis for hospitals, laboratories, and…
Sells to hospitals, pathology labs and research organisations needing tissue-based molecular profiling, and serves drug development teams in biotech and pharma. Targets clinical diagnostics and…
Financial Health
WeakWeak · Hiring · 3% CAGR over 4y
Location
POLARIS PHARMA LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops biopharmaceuticals for cancer and metabolic diseases, including the investigational enzyme therapy ADI‑PEG 20. Conducts clinical trials and provides contract development and manufacturing of…
Serves oncology and metabolic disease markets, including cancer treatment providers, clinical-trial partners and pharmaceutical or biotech companies seeking CDMO manufacturing partnerships.
Financial Health
WeakWeak · -6% CAGR over 2y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops liquid biopsy technology for cancer research, including the VTX-1 system that isolates and collects circulating tumour cells from blood samples. Provides tools and services that enable…
Serves cancer researchers, oncology laboratories, academic medical centres, biotech and pharmaceutical teams working on liquid biopsy, precision oncology and anti-metastatic therapy development.
Financial Health
WeakWeak
Location
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops genomics research technology and tools for single‑cell analysis. Provides the SimpleCell platform enabling single‑cell RNA sequencing experiments, sample processing and data generation for…
Sells to life science researchers, genomics laboratories, and research organisations running single-cell studies, from pilot projects to population-scale genomics.
Financial Health
DistressedDistressed · -14% CAGR over 4y
Location
Actigen Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsConducts research and clinical development of drug therapies for rare diseases, including mucopolysaccharidosis II (Hunter syndrome). Designs and runs patient-focused clinical trials and develops…
Serves patients and families affected by serious rare diseases, particularly MPS II/Hunter syndrome, alongside clinicians, patient advocacy groups, partners and healthcare stakeholders involved in…
Financial Health
StrongStrong · Hiring · 32% CAGR over 5y
Location
Develops and commercialises pharmaceutical treatments for rare diseases and specialty conditions. Operates a product portfolio and pipeline including therapies for metabolic, neurological, and…
Serves rare disease patients and their caregivers, particularly in the US, including people affected by conditions such as multiple sclerosis, cystinuria, hereditary angioedema, alkaptonuria and…
Location
YAQRIT LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops therapeutics for advanced liver disease. Conducts biomedical research and clinical trials targeting inflammatory pathways and gut–liver interactions, including microbiome-based treatments,…
Targets healthcare organisations and specialist liver disease clinicians treating patients with advanced liver disease, including primary sclerosing cholangitis, inflammatory bowel disease and…
Financial Health
StableStable · -11% CAGR over 4y
Location
OXCITAS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops computational platforms using machine learning, artificial intelligence and systems biology to analyse ageing mechanisms and support discovery of therapeutic interventions. Provides…
Serves businesses in life sciences, particularly pharmaceutical and biotech organisations seeking ageing-related drug discovery and development partnerships, with tailored platform offerings for…
Financial Health
StableStable · -16% CAGR over 4y
Location
DIAGNODUS LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · 0% CAGR over 4y
Location
Omnigen Biodata Ltd
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops biodata platforms and population health registries used for medical research, real‑world analytics, observational studies, and clinical trials, supporting analysis of individual and…
Serves health researchers, life sciences organisations, and healthcare or public health bodies conducting population health research, real-world analytics, observational studies and clinical trials.
Financial Health
StrongStrong · Growing, Hiring · 10% CAGR over 3y
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops therapeutic antibodies for cardiovascular disease. Lead candidate ISM‑001 inhibits the VEGF‑A165b isoform to promote blood vessel growth, aiming to treat conditions including chronic stable…
Targets the cardiovascular healthcare market, ultimately serving patients with chronic stable angina and peripheral arterial disease, alongside clinicians and healthcare providers treating…
Financial Health
StrongStrong · Hiring · 80% CAGR over 1y
Location
Ignota Labs Limited
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops AI-based bioinformatics and cheminformatics software for in‑silico toxicity prediction in drug development. Analyses clinical and preclinical data to identify causes of drug safety failures…
Sells to pharmaceutical and biotech companies seeking to revive failed or abandoned drug candidates, particularly teams responsible for preclinical to Phase 2 safety, toxicity assessment, and…
Financial Health
WeakWeak
Location
LUCIDA MEDICAL LTD
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops artificial intelligence software that analyses prostate MRI scans to assist clinicians in detecting and diagnosing prostate cancer. The Pi system evaluates imaging data to identify…
Serves healthcare providers, including NHS trusts, hospitals, radiology departments, urology teams and clinicians involved in prostate cancer diagnostic pathways.
Financial Health
StableStable · Hiring · 13% CAGR over 3y
Location
LI-COR BIOSCIENCES UK LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies laboratory imaging systems, scanners, reagents, and analysis software for molecular biology applications including Western blotting, protein and DNA gel imaging, ELISA assays,…
Serves life science researchers and laboratory teams in academia, biotech, pharmaceutical and regulated research settings, including scientists working on protein, cell, tissue and small-animal…
Financial Health
HealthyHealthy · -5% CAGR over 4y
Location
Genestack
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops data management and integration software for life science research. Provides platforms to catalogue, curate and search multi‑omics and imaging datasets, integrate with existing IT systems,…
Serves R&D, informatics and data teams at pharma, agriscience and consumer goods organizations, as well as life science researchers working with multi-omics, imaging and biological datasets.
Financial Health
DistressedDistressed · -22% CAGR over 4y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsSupplies life science research reagents including antibodies, recombinant proteins, cytokines and ELISA kits, along with molecular biology and nucleic acid isolation kits. Provides custom services…
Serves life science researchers and laboratory buyers in academia, biotech, pharma and biomedical research, including teams working in oncology, immunology, veterinary, plant, viral and molecular…
Financial Health
DistressedDistressed · -91% CAGR over 2y
Location
ANTIBODIES.COM LIMITED
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsSupplies antibodies, recombinant proteins, peptides, and ELISA assay kits for life science research. Offers primary and secondary antibodies and related reagents used in laboratory applications such…
Serves life science researchers, laboratory teams and new labs globally, including scientists conducting antibody-based applications such as western blot, IHC, flow cytometry and ELISA.
Financial Health
StrongStrong · Growing, Hiring · 43% CAGR over 4y
Location
RDP Life Sciences Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StableStable
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops biotechnology-based therapeutic treatments targeting diseases with unmet medical needs. Conducts pre-clinical research, including in vitro and in vivo studies, to evaluate and advance novel…
Financial Health
StrongStrong · Hiring · 32% CAGR over 2y
Location
BIOS HEALTH LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops AI-powered neural interfaces and software platforms that read and write nervous system signals to analyse neural data and develop digital therapeutics. Technology is used in research…
Serves life sciences and healthcare organisations, especially pharmaceutical, biotech and digital therapeutics partners developing treatments for chronic diseases, starting with cardiovascular…
Financial Health
WeakWeak · -26% CAGR over 2y
Location
John McNamara Consulting Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · 0% CAGR over 4y
Location
XSITU LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
ACRIA DX LTD
Trajectory
1y · 2024–NowFinancial Health
Insufficient historyInsufficient history
Location
PSYNOVA NEUROTECH LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · 0% CAGR over 5y
Location
CELLESTIAL HEALTH LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
HealthyHealthy · 0% CAGR over 1y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
GENEMUK LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · -68% CAGR over 4y
Location
IOTA Pharmaceuticals Limited
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · 0% CAGR over 2y
Location
Discovery Pharma Consulting (UK) Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · 0% CAGR over 4y
Location
IMMUTRIN LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong
Location
Trey Consulting Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · 0% CAGR over 4y
Location
Blackhawk Innovation Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · 0% CAGR over 4y
Location
Accentbio Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · 0% CAGR over 4y
Location
Syntherix Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
WeakWeak
Location
Biotryp Therapeutics LTD
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StrongStrong · Growing, Hiring · 100% CAGR over 2y
Location
Agile Biomedical Consultants Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Unlock all 142 leads
Showing 50 of 142 — +92 more with verified decision-maker contacts, live data, and CRM sync.
How Cambridge biotech companies work and how to sell to them
What they do
Cambridge biotech companies usually monetise science before they monetise finished products. Therapeutic developers tend to work towards licence, co-development, milestone and royalty economics, with fee income limited until an asset is partnered or acquired. Diagnostics and enabling-platform businesses are more likely to sell assay development, sample processing, research services, software-adjacent analysis or access to proprietary methods. Pricing is often staged around feasibility, validation, preclinical or clinical work packages rather than simple seats or usage. For suppliers, that means budgets sit close to scientific proof points, patent position, grant or investor funding, and the next regulatory or partnering milestone.
Who they sell to
Most customers are specialist rather than mass-market: pharmaceutical R&D groups, clinical research teams, healthcare laboratories, academic units and research-led service providers. The first sponsor is often a scientific or clinical lead, with finance, legal, quality, information security and procurement joining once work moves beyond a pilot. Sales cycles tend to run in months because buyers need evidence packs, technical review, ethics or governance checks, and IP terms agreed before commitment. Smaller engagements may begin as direct scientist-to-scientist projects, while larger biopharma or public-sector work is more likely to involve formal vendor qualification, tendering or framework-style procurement.
What they buy
Most biotech firms tend to spend on tools and services that shorten the path from experiment to regulated evidence. Common categories include laboratory information management, electronic lab notebooks, quality management, clinical trial operations, regulatory affairs support, pharmacovigilance, secure document control, bioinformatics infrastructure, data engineering and cyber security. Finance and operational teams also buy accounting, tax, HR, payroll, insurance, recruitment and legal support, especially around IP, collaboration agreements and clinical contracts. Lab-facing buyers may need consumables, sample logistics, equipment maintenance and outsourced manufacturing or testing capacity, while lean management teams often prefer vendors that can work around grant, investor or milestone-driven budgets.
Why and how to sell to them
Biotech buyers tend to evaluate vendors when a scientific programme moves stage, a clinical trial application is being prepared, a quality system needs tightening, or new funding gives management permission to replace manual processes. Leadership hires in clinical operations, regulatory, finance or partnering are useful intent signals, as are lab moves, hiring in data roles and the appointment of outsourced clinical or manufacturing partners. Outbound messaging usually lands better when it connects to risk reduction: reproducible results, cleaner audit trails, fewer hand-offs between contractors, clearer budget control and evidence that stands up to diligence by regulators, partners and investors.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Cambridge
Related directories
Frequently asked questions
How many biotech companies are there in the Cambridge?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the Cambridge?↓
What do biotech companies in the Cambridge actually do?↓
How does Cambridge biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the Cambridge?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 142 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.